A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

MLA

Mack, Isabelle, et al. “A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.” Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association, vol. 20, no. 5, May 2022, p. 1039. EBSCOhost, https://doi.org/10.1016/j.cgh.2021.06.028.

APA

Mack, I., Schwille-Kiuntke, J., Mazurak, N., Niesler, B., Zimmermann, K., Mönnikes, H., & Enck, P. (2022). A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association, 20(5), 1039. https://doi.org/10.1016/j.cgh.2021.06.028

Chicago

Mack, Isabelle, Juliane Schwille-Kiuntke, Nazar Mazurak, Beate Niesler, Kurt Zimmermann, Hubert Mönnikes, and Paul Enck. 2022. “A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.” Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association 20 (5): 1039. doi:10.1016/j.cgh.2021.06.028.